Chance Scott shares insights on the benefits of evolving the role and integration of your reimbursement policy team to serve as market access partners and propellants, as well as the best practices for how to do so.
Chance Scott
Advertisement
Chance Scott is a partner in Guidehouse’s Life Sciences practice. Chance is the practice lead for Guidehouse's Market Access Center of Excellence for the pharmaceutical segment. Chance works with clients to develop comprehensive access strategies across pricing, value proposition development, and coding / reimbursement policy.
Articles by Chance Scott
While there has been an increase in discourse concerning drug pricing transparency in recent years, there is still a degree of misunderstanding. This is due to the healthcare industry's numerous stakeholders and their compelling interests. This research done by Guidehouse aims to clear the picture.
Advertisement
Latest Updated Articles
The Myth of Skyrocketing Drug Prices: A Closer Look at The US Gross to Net ProblemPublished: June 1st 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Thermo Fisher Enters $8.8 Billion Definitive Agreement to Acquire Clario Holdings
2
Investors Have Questions About GLP-1 Drug Prices Ahead of Eli Lilly and Novo Quarterly Statements: Report
3
FDA Announces New Biosimilar-Targeted Draft Guidance
4
Pharmaceutical Executive Daily: Lilly and NVIDIA Create AI Supercomputer
5
